ECSP034494A - Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales - Google Patents

Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales

Info

Publication number
ECSP034494A
ECSP034494A EC2003004494A ECSP034494A ECSP034494A EC SP034494 A ECSP034494 A EC SP034494A EC 2003004494 A EC2003004494 A EC 2003004494A EC SP034494 A ECSP034494 A EC SP034494A EC SP034494 A ECSP034494 A EC SP034494A
Authority
EC
Ecuador
Prior art keywords
trasferasa
proteino
farnesil
antitumor agents
new inhibitors
Prior art date
Application number
EC2003004494A
Other languages
English (en)
Inventor
F George Njoroge
Patrick A Pinto
Bama Santhanam
Alan B Cooper
Timothy J Guzi
Dinanath F Rane
Keith P Minor
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Bancha Vibulbhan
Kartik M Keertikar
John J Baldwin
Ge Li
Chia Yu Huang
Ray A James
Walter Robert Bishop
Jagdish A Desai
Carmen S Alvarez
Hugh Y Zhu
James J S Wang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP034494A publication Critical patent/ECSP034494A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe compuestos triciclicos novedosos representados por la fórmula (1,0) una prodroga de la misma o una sal o solvato farmacéuticamente aceptable del compuesto o de dicha prodroga útiles para inhibir la farnesil proteína transferasa. También se describen composiciones farmacéuticas que comprenden a tales compuestos, su preparación, como así también métodos para utilizarlos para tratar enfermedades proliferativas tales como el cáncer.
EC2003004494A 2000-08-30 2003-02-26 Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales ECSP034494A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
ECSP034494A true ECSP034494A (es) 2003-04-25

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004494A ECSP034494A (es) 2000-08-30 2003-02-26 Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales

Country Status (27)

Country Link
US (1) US20020198216A1 (es)
EP (1) EP1313725B1 (es)
JP (1) JP2004513885A (es)
KR (1) KR20030034161A (es)
CN (1) CN100384837C (es)
AR (1) AR033680A1 (es)
AT (1) ATE359281T1 (es)
AU (2) AU2001288451C1 (es)
BR (1) BR0113675A (es)
CA (1) CA2420673A1 (es)
CO (1) CO5640109A2 (es)
DE (1) DE60127846T2 (es)
EC (1) ECSP034494A (es)
ES (1) ES2284686T3 (es)
HK (1) HK1054548B (es)
HU (1) HUP0302942A3 (es)
IL (1) IL154528A0 (es)
MX (1) MXPA03001849A (es)
NO (1) NO20030918L (es)
NZ (1) NZ524246A (es)
PE (1) PE20020486A1 (es)
PL (1) PL361103A1 (es)
RU (1) RU2293734C9 (es)
SK (1) SK2292003A3 (es)
TW (1) TWI268280B (es)
WO (1) WO2002018368A1 (es)
ZA (1) ZA200301545B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
HU230273B1 (hu) * 2001-03-14 2015-11-30 Bristol-Myers Squibb Company Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
AU2002340139A1 (en) * 2001-10-09 2003-04-22 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
CN1617755A (zh) * 2001-11-30 2005-05-18 先灵公司 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
MXPA04005425A (es) * 2001-12-03 2004-10-11 Schering Corp Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US7714139B2 (en) * 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US20060281813A1 (en) * 2003-06-05 2006-12-14 Charles Rubin Methods of treating hyperproliferative cell disorders
CN1972712A (zh) * 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
ES2235611B2 (es) * 2003-07-25 2006-07-16 Universidade De Santiago De Compostela Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
BRPI0413384A (pt) * 2003-08-07 2006-10-17 Schering Corp inibidores da proteìna farnesil transferase como agentes antitumores
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
WO2006069208A2 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
RU2361587C1 (ru) * 2008-02-14 2009-07-20 Михаил Владимирович Кутушов Лекарственное средство для лечения онкологических заболеваний
CA2730190A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
EP3989956A1 (en) * 2019-06-28 2022-05-04 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IE68935B1 (en) * 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
KR20010081115A (ko) * 1998-12-18 2001-08-27 둘락 노먼 씨. 파르네실 단백질 트랜스퍼라제 억제제

Also Published As

Publication number Publication date
PE20020486A1 (es) 2002-06-14
KR20030034161A (ko) 2003-05-01
AU8845101A (en) 2002-03-13
EP1313725B1 (en) 2007-04-11
RU2293734C2 (ru) 2007-02-20
IL154528A0 (en) 2003-09-17
AR033680A1 (es) 2004-01-07
CN100384837C (zh) 2008-04-30
SK2292003A3 (en) 2003-08-05
AU2001288451C1 (en) 2008-03-06
ATE359281T1 (de) 2007-05-15
WO2002018368A1 (en) 2002-03-07
PL361103A1 (en) 2004-09-20
US20020198216A1 (en) 2002-12-26
NO20030918L (no) 2003-04-29
HUP0302942A3 (en) 2007-02-28
TWI268280B (en) 2006-12-11
JP2004513885A (ja) 2004-05-13
BR0113675A (pt) 2003-06-24
DE60127846D1 (en) 2007-05-24
HK1054548B (en) 2007-10-18
DE60127846T2 (de) 2008-03-06
ZA200301545B (en) 2004-06-22
HK1054548A1 (en) 2003-12-05
HUP0302942A2 (hu) 2003-12-29
MXPA03001849A (es) 2003-06-04
CO5640109A2 (es) 2006-05-31
RU2293734C9 (ru) 2007-10-10
CA2420673A1 (en) 2002-03-07
CN1471524A (zh) 2004-01-28
ES2284686T3 (es) 2007-11-16
AU2001288451B2 (en) 2007-05-24
NO20030918D0 (no) 2003-02-27
EP1313725A1 (en) 2003-05-28
NZ524246A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
ECSP034494A (es) Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
BR112022012641A2 (pt) Compostos tricíclicos substituídos
DOP2022000039A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
BR112022010383A2 (pt) Compostos tricíclicos substituídos
BR0206955A (pt) Ligantes de receptores de canabinóides
GT200400133AA (es) Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
PA8547701A1 (es) Nucleosidos 4 substituidos.
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
PA8591701A1 (es) Derivados de pirrolopirimidina
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
BR0308071A (pt) Inibidores da protéina farnesil transferase como agentes antitumores
BRPI0413384A (pt) inibidores da proteìna farnesil transferase como agentes antitumores
CR20250124A (es) Compuestos para el tratamiento del cáncer
UY28821A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.
CL2025002792A1 (es) Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
NI200700323A (es) 4-anilino-3-quinolinocarbonitrilo para el tratamiento de cáncer
MY138124A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
ECSP045249A (es) "inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales"
MX2025005365A (es) Compuestos triciclicos
AR127559A1 (es) Compuestos, composiciones y métodos